去甲肾上腺素：帕金森病的下一个治疗前沿。
Norepinephrine: the next therapeutics frontier for Parkinson's disease.
机构信息
Department of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, Detroit, Michigan USA.
出版信息
Transl Neurodegener. 2012 Jan 13;1(1):4. doi: 10.1186/2047-9158-1-4.
Abstract
Tissue concentrations of norepinephrine (NE) are markedly decreased in various regions of the Parkinson's disease (PD) brain. As in the substantia nigra pars compacta, neuronal dropout and Lewy bodies are prominent changes affecting the locus coeruleus, which is the source of ascending NErgic projections. Despite the major roles of NE throughout the brain, there has been only minimal exploration of pharmacological intervention with NErgic neurotransmission. Cognitive operations, "freezing" of gait, tremor, dyskinesia, REM sleep regulation, and other aspects of brain function are tied into signaling by NE, and there is also evidence that it may have a role in the neurodegenerative process itself. This article reviews the reported pharmacological experience in PD therapeutics.
摘要
帕金森病（PD）大脑的各个区域去甲肾上腺素（NE）的组织浓度明显降低。与黑质致密部一样，神经元丢失和路易体是影响蓝斑的突出变化，蓝斑是上行 NE 投射的来源。尽管 NE 在整个大脑中起着重要作用，但对 NE 神经传递的药物干预的探索还很有限。认知操作、步态冻结、震颤、运动障碍、REM 睡眠调节和大脑功能的其他方面都与 NE 的信号有关，也有证据表明它可能在神经退行性过程本身中发挥作用。本文综述了 PD 治疗中的报道的药理学经验。
相似文献
1
Norepinephrine: the next therapeutics frontier for Parkinson's disease.去甲肾上腺素：帕金森病的下一个治疗前沿。
Transl Neurodegener. 2012 Jan 13;1(1):4. doi: 10.1186/2047-9158-1-4.
2
In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts.使用神经黑色素敏感 MRI 检测帕金森病中黑质和蓝斑体积的损失：在两个队列中的复制研究。
PLoS One. 2023 Apr 13;18(4):e0282684. doi: 10.1371/journal.pone.0282684. eCollection 2023.
3
Targeting the norepinephrinergic system in Parkinson's disease and related disorders: The locus coeruleus story.针对帕金森病及相关疾病中的去甲肾上腺素能系统：蓝斑的故事。
Neurochem Int. 2017 Jan;102:22-32. doi: 10.1016/j.neuint.2016.11.009. Epub 2016 Nov 27.
4
Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.帕金森病黑质致密部神经元中的神经丝信使核糖核酸减少。
J Comp Neurol. 1993 Mar 15;329(3):328-36. doi: 10.1002/cne.903290304.
5
Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation.多巴胺 D2 受体是 REM 睡眠剥夺介导的黑质致密部神经元激活的关键因素。
Neuropharmacology. 2014 Jan;76 Pt A:118-26. doi: 10.1016/j.neuropharm.2013.08.024. Epub 2013 Sep 4.
6
Neuromelanin magnetic resonance imaging of substantia nigra and locus coeruleus in Parkinson's disease with freezing of gait.帕金森病冻结步态患者黑质和蓝斑的神经黑色素磁共振成像
Front Aging Neurosci. 2023 Feb 2;15:1060935. doi: 10.3389/fnagi.2023.1060935. eCollection 2023.
7
Locus coeruleus.蓝斑。
Cell Tissue Res. 2018 Jul;373(1):221-232. doi: 10.1007/s00441-017-2649-1. Epub 2017 Jul 7.
8
Prodromal non-motor symptoms of Parkinson's disease.帕金森病的前驱期非运动症状。
Neuropsychiatr Dis Treat. 2007 Feb;3(1):145-52. doi: 10.2147/nedt.2007.3.1.145.
9
Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse.新型 A30P α-突触核蛋白 BAC 转基因小鼠多巴胺而非去甲肾上腺素信号的区域特异性缺陷。
Neurobiol Dis. 2014 Feb;62:193-207. doi: 10.1016/j.nbd.2013.10.005. Epub 2013 Oct 10.
10
Norepinephrine: The redheaded stepchild of Parkinson's disease.去甲肾上腺素：帕金森病中备受冷落的角色。
Biochem Pharmacol. 2007 Jul 15;74(2):177-90. doi: 10.1016/j.bcp.2007.01.036. Epub 2007 Feb 3.
引用本文的文献
1
Exploratory Metabolomic and Lipidomic Profiling in a Manganese-Exposed Parkinsonism-Affected Population in Northern Italy.意大利北部锰暴露帕金森综合征患者群体的探索性代谢组学和脂质组学分析
Metabolites. 2025 Jul 20;15(7):487. doi: 10.3390/metabo15070487.
2
The effect of deep brain stimulation on cortico-subcortical networks in Parkinson's disease patients with freezing of gait: Exhaustive exploration of a basic model.脑深部电刺激对帕金森病冻结步态患者皮质-皮质下网络的影响：一个基本模型的详尽探索
Netw Neurosci. 2024 Oct 1;8(3):926-945. doi: 10.1162/netn_a_00376. eCollection 2024.
3
Metabolomic and Lipidomic Analysis of Manganese-Associated Parkinsonism: a Case-Control Study in Brescia, Italy.锰相关帕金森综合征的代谢组学和脂质组学分析：意大利布雷西亚的一项病例对照研究。
medRxiv. 2024 Sep 6:2024.09.04.24313002. doi: 10.1101/2024.09.04.24313002.
4
Vocal and tongue exercise in early to mid-stage Parkinson disease using the Pink1-/- rat.使用 Pink1-/- 大鼠进行帕金森病早中期的嗓音和舌部锻炼。
Brain Res. 2024 Aug 15;1837:148958. doi: 10.1016/j.brainres.2024.148958. Epub 2024 Apr 27.
5
Pink1-/- Rats Demonstrate Swallowing and Gastrointestinal Dysfunction in a Model of Prodromal Parkinson Disease.Pink1-/- 大鼠在帕金森病前驱期模型中表现出吞咽和胃肠道功能障碍。
Dysphagia. 2023 Oct;38(5):1382-1397. doi: 10.1007/s00455-023-10567-0. Epub 2023 Mar 22.
6
Recent Development of Nano-Carbon Material in Pharmaceutical Application: A Review.纳米碳材料在药物应用中的最新进展：综述
Molecules. 2022 Nov 4;27(21):7578. doi: 10.3390/molecules27217578.
7
Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.三环抗抑郁药去甲丙咪嗪与 L-DOPA 在 6-OHDA 损伤大鼠中的行为和神经化学相互作用。对帕金森病运动和精神功能的影响。
Psychopharmacology (Berl). 2022 Nov;239(11):3633-3656. doi: 10.1007/s00213-022-06238-x. Epub 2022 Sep 30.
8
Closing the loop for patients with Parkinson disease: where are we?为帕金森病患者闭环：我们在哪里？
Nat Rev Neurol. 2022 Aug;18(8):497-507. doi: 10.1038/s41582-022-00674-1. Epub 2022 Jun 9.
9
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.帕金森病运动和非运动症状的非多巴胺能治疗方法的最新进展。
Curr Neuropharmacol. 2023;21(8):1806-1826. doi: 10.2174/1570159X20666220222150811.
10
Sirtuins and Autophagy in Age-Associated Neurodegenerative Diseases: Lessons from the Model.衰老相关神经退行性疾病中的沉默调节蛋白与自噬：来自该模型的启示
Int J Mol Sci. 2021 Nov 12;22(22):12263. doi: 10.3390/ijms222212263.
本文引用的文献
1
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).随机对照临床试验氟哌噻吨美利曲辛治疗帕金森病运动障碍（FJORD 研究）。
Neurology. 2012 Jul 10;79(2):163-9. doi: 10.1212/WNL.0b013e31825f0451. Epub 2012 Jun 27.
2
The locus ceruleus norepinephrine system: functional organization and potential clinical significance.蓝斑去甲肾上腺素系统：功能组织及潜在临床意义。
Neurology. 2009 Nov 17;73(20):1699-704. doi: 10.1212/WNL.0b013e3181c2937c.
3
Neuroinflammation in Parkinson's disease: a target for neuroprotection?帕金森病中的神经炎症：神经保护的一个靶点？
Lancet Neurol. 2009 Apr;8(4):382-97. doi: 10.1016/S1474-4422(09)70062-6.
4
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.托莫西汀治疗帕金森病执行功能障碍：一项开放性试点研究。
Mov Disord. 2009 Jan 30;24(2):277-82. doi: 10.1002/mds.22307.
5
L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.左旋二羟基苯丝氨酸（屈昔多巴）治疗直立性低血压：欧洲经验
Clin Auton Res. 2008 Mar;18 Suppl 1:25-9. doi: 10.1007/s10286-007-1005-z. Epub 2008 Mar 27.
6
Norepinephrine: The redheaded stepchild of Parkinson's disease.去甲肾上腺素：帕金森病中备受冷落的角色。
Biochem Pharmacol. 2007 Jul 15;74(2):177-90. doi: 10.1016/j.bcp.2007.01.036. Epub 2007 Feb 3.
7
Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.瑞波西汀治疗帕金森病伴重度抑郁发作患者4个月的疗效
Gen Hosp Psychiatry. 2006 Jan-Feb;28(1):59-64. doi: 10.1016/j.genhosppsych.2005.07.005.
8
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system.帕金森病中的抑郁：边缘系统中多巴胺和去甲肾上腺素神经支配的丧失。
Brain. 2005 Jun;128(Pt 6):1314-22. doi: 10.1093/brain/awh445. Epub 2005 Feb 16.
9
The brain-stem lesions in Parkinsonism.帕金森病中的脑干病变。
J Neurol Neurosurg Psychiatry. 1953 Nov;16(4):213-26. doi: 10.1136/jnnp.16.4.213.
10
Where does parkinson disease pathology begin in the brain?帕金森病的病理变化在大脑中从何处开始？
J Neuropathol Exp Neurol. 2002 May;61(5):413-26. doi: 10.1093/jnen/61.5.413.
Zotero 插件